Aprea Therapeutics (APRE) announced the appointment of Eugene Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea following the Company’s recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Announces Financing and Early Trial Response
- Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- Aprea Therapeutics prices 6.29M shares at 89c in private placement
- Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
- Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook